Literature DB >> 7261949

The risks of asymptomatic hyperuricaemia and the use of uricosuric diuretics.

M W Johnson, W E Mitch.   

Abstract

Introduction of new uricosuric diuretics will be accompanied by the unknown risk factors associated with the use of any new drug, as demonstrated by reports of hepatic toxicity associated with ticrynafen. In addition to unexpected reactions, there are potential risks related to induction of uricosuria, which are serious and have been reported to occur. More importantly, the risk of developing clinical gout or coronary heart disease due to mild asymptomatic hyperuricaemia appears minimal, so indications for the use of uricosuric diuretics are limited. If a uricosuric diuretic is thought necessary (and is available), it would seem prudent to measure the daily excretion rate of uric acid to identify those patients with hyperuricaemia related to overproduction of uric acid. A uricosuric diuretic should be avoided in those patients, as well as in patients with uric acid stones, and possibly in those with calcium stones. A uricosuric diuretic might be useful for patients with hypertension who also have hyperuricaemia due to a low excretion of uric acid.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7261949     DOI: 10.2165/00003495-198121030-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  27 in total

1.  Renal outcomes of gout and hyperuricemia.

Authors:  W J Fessel
Journal:  Am J Med       Date:  1979-07       Impact factor: 4.965

2.  Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects.

Authors: 
Journal:  Circulation       Date:  1972-05       Impact factor: 29.690

3.  Renal disease in primary gout.

Authors:  K A Barlow; L J Beilin
Journal:  Q J Med       Date:  1968-01

4.  The relationship of serum uric acid to risk factors in coronary heart disease.

Authors:  A R Myers; F H Epstein; H J Dodge; W M Mikkelsen
Journal:  Am J Med       Date:  1968-10       Impact factor: 4.965

5.  Correlations among hyperuricemia, hypercholesterolemia, coronary disease and hypertension.

Authors:  A P Hall
Journal:  Arthritis Rheum       Date:  1965-10

6.  Acute renal failure during treatment with ticrynafen.

Authors:  H Sawa; H Yamakawa; L E Renjel; M Fernandes
Journal:  JAMA       Date:  1980 Feb 22-29       Impact factor: 56.272

7.  Ticrynafen: a new thiazid-like but uricosuric antihypertensive diuretic.

Authors:  E D Frohlich
Journal:  N Engl J Med       Date:  1979-12-20       Impact factor: 91.245

8.  Clinical study of ticrynafen. A new diuretic, antihypertensive, and uricosuric agent.

Authors:  M Nemati; M C Kyle; E D Freis
Journal:  JAMA       Date:  1977-02-14       Impact factor: 56.272

9.  Comparative effects of ticrynafen and hydrochlorothiazide in the treatment of hypertension.

Authors: 
Journal:  N Engl J Med       Date:  1979-08-09       Impact factor: 91.245

10.  Uric acid saturation in calcium nephrolithiasis.

Authors:  F L Coe; A L Strauss; V Tembe; S Le Dun
Journal:  Kidney Int       Date:  1980-05       Impact factor: 10.612

View more
  2 in total

1.  Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study.

Authors:  Shih-Yang Chen; Ching-Lang Chen; Ming-Lai Shen
Journal:  Clin Rheumatol       Date:  2006-05-11       Impact factor: 2.980

Review 2.  Angiotensin I converting enzyme inhibitors and the renal excretion of urate.

Authors:  W P Leary; A J Reyes
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.